Is Addex Therapeutics Ltd (ADXN.SW) a Buy, Sell, or Hold?
SIX : ADXN.SW
Addex Therapeutics Ltd
$0.0398 CHF
$0.0 (-1.49%)
- Volume
- 206.88K
- Average Volume
- 162.07K
- Market Capitalization
- $6.05M
- P/E Ratio
- -0.72
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.09
- Year Low
- $0.03
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.97
Company Overview
SIX
Timothy Mark Dyer
Biotechnology
Healthcare
ADXN.SW
3
CH
CHF
Liquidity Metrics
0.03
0.97
0.97
0.77
0.00
Sales & Valuation
$173K
67.46
2.07
-2.58
-0.01
Profitability
-$0.06
-$6.73M
-7775.20%
-7901.66%
-131.35%
-146.41%
P/E Metrics
-0.72
0.00
0.00
Analyst Price Target & Rating
2/5
1 Analysts
%
Financial Health Scores
-107.08
2/9
-$32560
$4.76M
$1.47M
-$4.79M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Mikhail Kalinichev | Head of Translational Science |
| Lénaic Teyssédou | Head of Finance |
| Timothy Mark Dyer | Co-Founder, Chief Executive Officer & Director |
| Roger G. Mills | Chief Medical Officer & Director |
Poll Results
No votes yet today — be the first to share your view!
About Addex Therapeutics Ltd (SIX:ADXN.SW) Stock
Addex Therapeutics Ltd, a biopharmaceutical company in its development phase, specializes in the discovery, progression, and commercialization of small-molecule pharmaceutical products designed to address central nervous system (CNS) conditions. Based in Geneva, Switzerland, the firm's core research centers on identifying oral small molecule allosteric modulators that interact with G-protein coupled receptors. Its leading clinical programs feature Dipraglurant, intended for the treatment of levodopa-induced dyskinesia in Parkinson's disease and dystonia; ADX71149, targeting epilepsy and various other neurological disorders; and GABAB PAM, developed to combat addiction. Addex has established strategic licensing and collaborative partnerships with organizations including Janssen Pharmaceutic ... als Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002, the company changed its name from Addex Pharmaceuticals Ltd to its current designation in March 2012.
Frequently Asked Questions
-
What is the current Addex Therapeutics Ltd (ADXN.SW) stock price?
-
Addex Therapeutics Ltd(SIX:ADXN.SW) stock price is $0.0398 in the last trading session. During the trading session, ADXN.SW stock reached the peak price of $0.085 while $0.0336 was the lowest point it dropped to. The percentage change in ADXN.SW stock occurred in the recent session was --1.49% while the dollar amount for the price change in ADXN.SW stock was -$0.0.
-
ADXN.SW's industry and sector of operation?
-
The SIX listed ADXN.SW is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ADXN.SW?
-
Mikhail Kalinichev | Head of Translational Science
Lénaic Teyssédou | Head of Finance
Timothy Mark Dyer | Co-Founder, Chief Executive Officer & Director
Roger G. Mills | Chief Medical Officer & Director
| -
How many employees does ADXN.SW have?
-
Number of ADXN.SW employees currently stands at 3. ADXN.SW operates from Chemin des Mines, 9, Geneva, GE 1202, CH.
-
Link for ADXN.SW official website?
-
Official Website of ADXN.SW is: https://www.addextherapeutics.com
-
How do I contact ADXN.SW?
-
ADXN.SW could be contacted at phone #41 22 884 1555 and can also be accessed through its website. ADXN.SW operates from Chemin des Mines, 9, Geneva, GE 1202, CH.
-
How many shares of ADXN.SW are traded daily?
-
The average number of ADXN.SW shares traded daily for last 3 months was 162.07K.
-
What is the market cap of ADXN.SW currently?
-
The market value of ADXN.SW currently stands at $6.05M with its latest stock price at $0.0398